2014 Q4 Form 10-Q Financial Statement

#000156459014005463 Filed on November 12, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.550M $1.710M
YoY Change
% of Gross Profit
Research & Development $5.050M $2.000M $1.134M
YoY Change 76.37%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $10.60M $5.949M $2.552M
YoY Change 133.11%
Operating Profit -$5.949M -$2.552M
YoY Change 133.11%
Interest Expense $70.00K $30.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$10.53M -$5.919M -$2.549M
YoY Change 132.21%
Income Tax $0.00 $0.00 -$13.00K
% Of Pretax Income
Net Earnings -$10.53M -$5.919M -$2.536M
YoY Change 133.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.110M -$292.9K
COMMON SHARES
Basic Shares Outstanding 20.21M
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.1M $51.70M
YoY Change
Cash & Equivalents $21.90M $25.70M $15.69M
Short-Term Investments $82.20M $26.00M
Other Short-Term Assets $1.900M $300.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $106.0M $52.02M
YoY Change 104.65%
LONG-TERM ASSETS
Property, Plant & Equipment $48.00K $14.00K
YoY Change 500.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $48.00K $2.084M
YoY Change 300.0%
Total Long-Term Assets $96.00K $2.098M
YoY Change 380.0%
TOTAL ASSETS
Total Short-Term Assets $106.0M $52.02M
Total Long-Term Assets $96.00K $2.098M
Total Assets $106.1M $54.12M
YoY Change 104.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $440.0K $569.0K
YoY Change -27.39%
Accrued Expenses $1.200M $500.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.724M $2.412M
YoY Change 78.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $216.0K $165.0K
YoY Change -6.09%
Total Long-Term Liabilities $216.0K $165.0K
YoY Change -6.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.724M $2.412M
Total Long-Term Liabilities $216.0K $165.0K
Total Liabilities $2.940M $2.577M
YoY Change 67.62%
SHAREHOLDERS EQUITY
Retained Earnings -$40.89M -$30.36M
YoY Change 217.39%
Common Stock $144.2M
YoY Change 6450.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $103.2M -$23.03M
YoY Change
Total Liabilities & Shareholders Equity $106.1M $54.12M
YoY Change 104.76%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$10.53M -$5.919M -$2.536M
YoY Change 133.4%
Depreciation, Depletion And Amortization $10.00K $0.00
YoY Change
Cash From Operating Activities -$4.960M -$4.090M
YoY Change 18.66%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$56.90M -$1.430M
YoY Change
Cash From Investing Activities -$56.93M -$1.440M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 58.08M -550.0K
YoY Change 51.17%
NET CHANGE
Cash From Operating Activities -4.960M -4.090M
Cash From Investing Activities -56.93M -1.440M
Cash From Financing Activities 58.08M -550.0K
Net Change In Cash -3.810M -6.080M
YoY Change -111.13%
FREE CASH FLOW
Cash From Operating Activities -$4.960M -$4.090M
Capital Expenditures -$40.00K $0.00
Free Cash Flow -$4.920M -$4.090M
YoY Change 17.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001604464
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12000
CY2013Q4 us-gaap Assets
Assets
51828000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
606000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
432000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1524000
CY2014Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
25996000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
193000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8000
CY2013Q4 us-gaap Liabilities
Liabilities
1754000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
51808000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
230000
CY2013Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
331000
CY2013Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
155000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20212889
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25703000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51615000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2014Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4241000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1708000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
868000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
5949000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2552000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5949000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2552000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5919000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2549000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-5919000
us-gaap Share Based Compensation
ShareBasedCompensation
4328000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Atara Biotherapeutics, Inc.
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
977778
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1337501
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-2536000
us-gaap Net Income Loss
NetIncomeLoss
-17479000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
910839
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-11017000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
54120000
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51828000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30362000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12883000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-23029000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12951191
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1410507
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-13.07
us-gaap Depreciation
Depreciation
4000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-4.20
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1017000
us-gaap Share Based Compensation
ShareBasedCompensation
1017000
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
2000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
34000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-37000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
2200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11671000
us-gaap Interest Income Other
InterestIncomeOther
8000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17501000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5190000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-22000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
27000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
323000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
52022000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2084000
CY2014Q3 us-gaap Assets
Assets
54120000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
569000
CY2014Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
500000
CY2014Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
63000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1280000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2412000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
165000
CY2014Q3 us-gaap Liabilities
Liabilities
2577000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7344000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2200000
CY2013Q4 atra Notes Receivable From Stockholders Equity
NotesReceivableFromStockholdersEquity
-335000
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1509712
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12003891
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1509712
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12003891
CY2013Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1134000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9332000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2057000
CY2013Q3 atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
550000
atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
1066000
atra Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
550000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7162000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2591000
us-gaap Operating Expenses
OperatingExpenses
17560000
us-gaap Operating Expenses
OperatingExpenses
5198000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17560000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5198000
CY2014Q3 us-gaap Interest Income Other
InterestIncomeOther
30000
CY2013Q3 us-gaap Interest Income Other
InterestIncomeOther
3000
us-gaap Interest Income Other
InterestIncomeOther
59000
us-gaap Net Income Loss
NetIncomeLoss
-5217000
CY2014Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-11000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-11000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5930000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2536000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-17490000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5217000
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.59
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-5.73
us-gaap Other Noncash Expense
OtherNoncashExpense
750000
us-gaap Depreciation
Depreciation
3000
atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
251000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
28618000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26428000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
14963000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11483000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15690000
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
249000
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
3000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
523000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
512000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-92000
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
11000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
440000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
542000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
169000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
186000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3477000
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
337000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
13500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
15087000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12187000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-25912000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4207000
us-gaap Stock Issued1
StockIssued1
750000
atra Issuance Of Convertible Preferred Stock In Exchange For License
IssuanceOfConvertiblePreferredStockInExchangeForLicense
1003000
atra Change In Obligation To Issue Convertible Preferred Stock
ChangeInObligationToIssueConvertiblePreferredStock
-1003000
atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
65000
atra Issuance Of Common Stock Upon Vesting Of Stock Awards
IssuanceOfCommonStockUponVestingOfStockAwards
80000
atra Change In Other Long Term Liabilities Related To Non Vested Stock Awards
ChangeInOtherLongTermLiabilitiesRelatedToNonVestedStockAwards
-65000
atra Restricted Stock Issued To Related Party In Exchange For Notes Receivable
RestrictedStockIssuedToRelatedPartyInExchangeForNotesReceivable
331000
atra Offering Costs In Anticipation Of Initial Public Filing Included In Accrued Liabilities And Accounts Payable
OfferingCostsInAnticipationOfInitialPublicFilingIncludedInAccruedLiabilitiesAndAccountsPayable
407000
us-gaap Income Taxes Paid
IncomeTaxesPaid
13000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
209959
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these combined and consolidated financial statements include the fair value of common stock, the fair value of preferred stock and estimates related to clinical trial accruals. Actual results could differ materially from those estimates. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We place cash and cash equivalents in the custody of financial institutions that management believes are of high credit quality, which at times, may be in excess of the amount insured by the Federal Deposit Insurance Corporation. We also have short-term investments in money market funds, corporate bonds and commercial paper backed by US Government or private insurers, which can be subject to certain credit risk. However, we mitigate the risks by investing in high-grade instruments, limiting our exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain risks and uncertainties and believe that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, our product candidates; performance of third-party clinical research organizations and manufacturers upon which we rely; development of sales channels; protection of our intellectual property; litigation or claims against us based on intellectual property, patent, product, regulatory or other factors; and our ability to attract and retain employees necessary to support our growth. </p></div>
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
26007000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2014Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
25996000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
24917000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
1090000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2014Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.7692
atra Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
atra Investment Maturity Period
InvestmentMaturityPeriod
P90D
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26007000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
24906000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1090000
CY2014Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
25996000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
atra Expense Recognized On Employee Awards Subject To Service And Performance Conditions
ExpenseRecognizedOnEmployeeAwardsSubjectToServiceAndPerformanceConditions
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12930215
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6594208
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5983828
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
209959
CY2012Q3 us-gaap License Costs
LicenseCosts
250000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
31900
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2014-10-31
CY2014Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12298515
CY2014Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12298515
CY2014Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
74572000
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
95423541
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
61091000
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
95423541
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
102774840
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The stockholders of Nina, Pinta and Santa Maria exchanged three shares of each company’s preferred stock for one share of Atara preferred stock (a collective nine-for-one basis).
us-gaap Convertible Preferred Stock Settlement Terms
ConvertiblePreferredStockSettlementTerms
Each share of convertible preferred stock, subject to certain anti-dilution adjustments, will be automatically converted into one fully paid and nonassessable share of common stock at the applicable conversion rate upon the earlier of: (i) an initial public offering with a pre-initial public offering valuation that results in a price to the public of at least three times the Series B issue price (reduced to 1.6 times following the Recapitalization—see Note 2)
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
162461535
atra Cancellation Of Shares Authorized Increase Decrease For Period
CancellationOfSharesAuthorizedIncreaseDecreaseForPeriod
923076
atra Tender Of Shares Authorized Increase Decrease For Period
TenderOfSharesAuthorizedIncreaseDecreaseForPeriod
161538459
atra Stock Authorized During Period Shares Period Increase Decrease
StockAuthorizedDuringPeriodSharesPeriodIncreaseDecrease
17948717
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
17948717
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
644710
atra Cancellation Of Outstanding Shares Increase Decrease For Period
CancellationOfOutstandingSharesIncreaseDecreaseForPeriod
923076
atra Tender Of Shares Outstanding Increase Decrease For Period
TenderOfSharesOutstandingIncreaseDecreaseForPeriod
11725525
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
1302835
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
147116
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
59761
CY2013Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2201000
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15133178
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
432000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4261774
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
144951
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
9492565
CY2014Q1 atra Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Recapitalization Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRecapitalizationShares
8437856
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1054709
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
36058
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
66153
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
966190
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.133
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.045
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.402
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.619
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
8.593
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.561
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
209959
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.55
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.55
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M17D

Files In Submission

Name View Source Status
0001564590-14-005463-index-headers.html Edgar Link pending
0001564590-14-005463-index.html Edgar Link pending
0001564590-14-005463.txt Edgar Link pending
0001564590-14-005463-xbrl.zip Edgar Link pending
atra-10q_20140930.htm Edgar Link pending
atra-20140930.xml Edgar Link completed
atra-20140930.xsd Edgar Link pending
atra-20140930_cal.xml Edgar Link unprocessable
atra-20140930_def.xml Edgar Link unprocessable
atra-20140930_lab.xml Edgar Link unprocessable
atra-20140930_pre.xml Edgar Link unprocessable
atra-ex311_20140930219.htm Edgar Link pending
atra-ex312_20140930220.htm Edgar Link pending
atra-ex321_20140930221.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending